Granzyme K Knockout Mice Exhibit Reduced Loss of Function with Age

A rising level of chronic inflammatory signaling in the absence of any provoking infection or injury is characteristic of aging, and a strong driver of tissue dysfunction. It arises from multiple mechanisms that maladaptively provoke the sensors and regulatory systems that control inflammation. These mechanisms include the presence of lingering senescent cells that secrete pro-inflammatory signals, the reactions of immune cells to the damage and metabolic waste they encounter in aged tissues, and forms of damage inside cells, such as mislocalized mitochondrial DNA, that triggers sensors evolved to detect pathogens. It would be hard to eliminate age-related inflammation without first eliminating a very large fraction of the cell and tissue damage that drives aging. A worthy goal, of course.

Despite the evident harms done by chronic inflammation, it is far from the only meaningful contribution to degenerative aging as a whole. It is a feature, a consequence of damage, a cause of further damage, but it doesn't act alone. Today's open access paper is an interesting demonstration of that point. The authors discovered that mice without active granzyme K signaling exhibit a slowed age-related deterioration of many measures of cell and tissue function. This occurs without any reduction in the chronic inflammation of aging, however, despite the fact that granzyme K is primarily secreted by T cells, is cytotoxic, and is known to engage with pro-inflammatory pathways. This study shows that granzyme K must be accelerating tissue aging via non-inflammatory mechanisms, which is an unexpected outcome.

Granzyme K is a driver of age-related tissue remodeling and functional decline independently of age-associated immune dysfunction

Among the many systems affected during biological aging, the immune compartment undergoes some of the most striking and consequential changes. Within this compartment, CD8+ T cells stand out as arguably the most affected by the aging process, with severely diminished naive CD8+ T cells, and marked evidence of dysfunction across memory phenotype cells, including both virtual memory T (Tvm) cells and conventional memory T (Tmem) cells. Strikingly, recent studies demonstrate that aging of the immune system, and of T cells in particular, can actively precipitate systemic aging. Studies indicate that T cells mediate these processes in part via the production of pro-inflammatory mediators.

Within this aging context, granzyme K (GzmK), a trypsin-like serine protease produced predominantly by CD8+ T cells, but also by γδ T cells, natural killer (NK) cells, and macrophages, has emerged as a key molecule of interest. Unlike other granzyme family members, which are associated with cytotoxicity, GzmK appears to be primarily pro-inflammatory, able to drive inflammation by activating PAR-1 and PAR-2 signaling, inducing cytokine and chemokine expression, and enhancing endothelial and myeloid-cell activation. Further, it was recently shown to activate the complement pathway and induce cellular senescent phenotypes in vitro. Consistent with these functions, it is strongly associated with a variety of inflammatory diseases in humans.

We show that GzmK protein is substantially increased with age in mice, uniquely within the T cell compartment and predominantly within conventional memory CD8+ T cells. Using young and aged GzmK-deficient (GzmK-/-) mice, we investigate the role of GzmK in driving key hallmarks of immune and organismal aging. GzmK deficiency over a lifespan could not attenuate systemic inflammaging, as measured by increases in serum inflammatory cytokines such as IL-6 and MCP-1. Moreover, the elevation of C3a in the serum of aged mice was not reduced in the absence of GzmK. Indeed, the reversal of the aging serum proteomic profile in GzmK-/- mice appeared to reflect activity at the level of tissues, with reduced serum abundance of intracellular proteins, including mitochondrial proteins, indicative of cellular turnover, and tissue enzymes such as ALT, AST, and ALDOB, indicative of organ stress and dysfunction. Consistent with this, GzmK deficiency had no impact on immune aging, either at steady state or following challenge.

Collectively, these findings indicate that GzmK acts locally within tissues to drive age-associated decline, rather than systemically to promote inflammaging or immune dysfunction.

FGF13 Overexpression Improves Astrocyte Function to Slow Cognitive Aging in Mice

One of the ways in which the research community finds potential targets for novel anti-aging therapies is to first establish which genes exhibit altered expression level with age in cells of interest, then see whether restoring youthful expression level of that gene produces useful results. Finding altered levels of expression is a fairly rapid process these days; much of the mapping has already been accomplished, and it becomes a matter of searching databases. Going gene by gene to establish effects of restored youthful expression remains a painfully slow process, unfortunately, but one that yields the occasional promising discovery such as the work on FGF13 in astrocytes noted here.

Aging is an intrinsic biological process; specifically, brain aging leads to cognitive decline, memory loss, and numerous neurodegenerative diseases. Fibroblast growth factor 13 (FGF13) is expressed in the central nervous system (CNS) and plays a critical role in several neuropathological conditions; however, the specific role of FGF13 in brain aging remains unclear. In this study, screening of public gene expression databases revealed that FGF13 is significantly downregulated in the brain tissues of aging mice and macaques, particularly within the medial prefrontal cortex (mPFC) and astrocytes.

Specific knockout of FGF13 in cortical astrocytes accelerates the aging phenotype and impairs neurological function in mice. Conversely, overexpression of FGF13 effectively delays the aging process and ameliorates aging-induced cognitive impairment. RNA-seq analysis indicated that FGF13 primarily influences astrocyte-mediated inflammatory responses and cellular autophagy.

Mechanistically, FGF13 targets and binds to Phafin2, promoting autophagy in astrocytes. Homeostatic astrocytes not only ameliorate neuronal damage but also reduce the release of inflammatory factors by microglia, playing a crucial role in mitigating the aging process in mice. In summary, FGF13 improves the cerebral microenvironment by regulating astrocyte function, ultimately exerting an anti-aging effect.

Link: https://doi.org/10.1111/acel.70784

Cerebrospinal Fluid Flow Waves Decline in the Aging Brain

Cerebrospinal fluid is manufactured by the choroid plexus, flows through the brain, and drains into the body via the glymphatic system. This current carries away metabolic waste from the brain, particularly during sleep. Unfortunately cerebrospinal flow and drainage declines with age, allowing the buildup of metabolic waste in the brain, such as the protein aggregates that contribute to neurodegenerative conditions. Evidence suggests this to be a meaningful contribution to degenerative aging in the brain. Most research in recent years has focused on drainage, but here researchers look at the flow of cerebrospinal fluid in the brain more generally.

Cerebrospinal fluid (CSF) circulates around and within brain tissue, performing multiple functions, including cushioning the brain and transporting solutes from brain tissue to brain exit routes. Prior studies measuring large-scale CSF flow in older humans have reported conflicting results. These prior studies examined CSF flow during daytime wakefulness, but both human and rodent studies have shown that brain hemodynamics and CSF circulation are strongly sleep dependent. During young adult non-rapid eye movement (NREM) sleep, large-amplitude low-frequency waves of CSF flow appear. These sleep-dependent fluid waves are influenced by both low-frequency neural oscillations and vascular dynamics.

In NREM sleep, large-scale neuronal firing reorganizes into low-frequency (0.5-4 Hz) oscillatory patterns known as slow waves that are detectable via electroencephalogram (EEG). These neural slow wave events modulate the cerebrovasculature and generate low-frequency waves in cerebral blood volume. Because of the fixed volume of the skull, these blood volume oscillations in turn drive large-amplitude, low-frequency pulsatile waves of CSF flow during sleep, Aging is associated with substantial disruptions to sleep architecture, including more fragile, fragmented sleep and reduced EEG slow wave power. This sleep fragmentation and loss of slow waves in aging could, in theory, lead to loss of CSF flow during sleep.

Here we imaged large-scale CSF flow and hemodynamics in young (18-39 years) and older (60-84 years) adults during nighttime sleep. Sleep-dependent CSF flow was reduced in older adults, and was linked to reduced EEG slow wave power, decreased global hemodynamic oscillations and gray matter atrophy. Using sensory and vasoactive stimuli to drive CSF flow, we found that both neural and cerebrovascular changes contributed to this disruption. These results demonstrate reduced CSF flow during sleep in human aging, before disease onset, and identify parallel neural and hemodynamic mechanisms contributing to this decline.

Link: https://doi.org/10.1038/s43587-026-01270-4

Aging Clocks May Reflect Disease Burden in Addition to Aging in Many Circumstances

When should we consider an age-related condition as being something distinct from aging? To what degree are aging clocks measuring burden of disease rather than burden of degenerative aging? These are questions that are difficult to provide generalized answers for without a consensus, very detailed definition of aging. It is possible to look at specific examples, however, in which it seems obvious and sensible to declare that the burden of that specific disease is distinct from what we might think of as aging, even given that the disease is age-related and arises from processes that we consider to cause aging. Infection leading to sepsis for example. Or later stages of cancer.

The authors of today's open access paper argue for aspects of cancer to be considered distinctly from aspects of aging. Cancer is clearly age-related and incidence of cancer is vastly greater in old age as the result of greater mutational damage, loss of immune surveillance, a more inflammatory environment, and other aspects of aging. Once cancer has developed, however, one might argue that a range of measures currently used to assess aging cease to reflect aging alone and start to reflect some combination of aging and the cancer.

Should we consider that having cancerous tissue inherently accelerates aging? In the not-all-that-useful definition of aging as an increased risk of mortality over time due to intrinsic causes, maybe so. But it doesn't seem entirely clear that it is otherwise helpful to think of tumors as inherently accelerating aging, in the context of any more detailed definition of aging as a process. On the other side of the coin, cancer does generate chronic inflammation and other metabolic disarray, and we all seem fairly comfortable in considering that these factors do accelerate aging regardless of cause. This might all be largely academic, if not for the existence of aging clocks, attempts to make use of aging clocks in the assessment of aging, and the pressing need for a consensus definition of aging at the detail level to better steer research and development.

Blood-based PhenoAge may reflect disease burden rather than biological aging in cancer

PhenoAge, a blood-based biological aging clock, is associated with cancer outcomes, a finding taken as evidence that biological aging shapes prognosis. PhenoAge weights each component by a coefficient estimated to predict mortality in the U.S. general population (NHANES), and these coefficients were held fixed here, as in standard works on PhenoAge and cancer. Across four biologically distinct cancers, PhenoAge predicted outcome. Yet PhenoAge acceleration rose with tumor stage and added little to established clinicopathologic factors. Furthermore, its association with survival was carried by one or two routine components that differed by cancer and by endpoint, and this was reproduced when its population-derived weights were replaced by an unweighted +1 or -1. This pattern is not what a general measure of aging would show. A simpler explanation is that PhenoAge is sensitive to the systemic consequences of malignancy, which are already reflected in the routine blood tests it happens to contain.

Components of PhenoAge such as red blood cell distribution width, albumin, lymphocyte percentage and alkaline phosphatase reflect inflammation, nutritional status, immune function, and organ or tumor burden, all known to influence cancer outcomes. PhenoAge integrates these abnormalities, weights them according to a reference population, and expresses them as a "biological age." An association between accelerated PhenoAge and poor cancer outcomes can invite mechanistic conclusions about aging that PhenoAge itself does not establish. Our findings do not imply that biological aging is irrelevant to cancer; different clocks measure different things, and we tested only one. Rather, our findings suggest that studying aging in oncology will require measures whose signal can be distinguished from the inflammatory, nutritional, hematologic, and organ-specific consequences of the cancer and its treatment.

Senescent Macrophages in Osteoporosis

The burden of senescent cells increases in later life and contributes to the chronic inflammation and disruption of tissue structure and function that are characteristic of aging. The innate immune cell population of macrophages can enter the senescent state just like other cell types, and are thought to be particularly influential in the pathologies of aging. There has been some debate over the years as to the degree to which early markers of senescence are useful in identifying macrophage senescence, however, and thus whether early studies were correct. It can be challenging to distinguish maladaptively inflammatory macrophages versus senescent macrophages via simple markers of cellular senescence. It remains the case that the research community considers macrophage senescence to be influential in aging; as an example, this review is focused on the contribution of senescent macrophages to osteoporosis, the age-related loss of bone mineral density that arises from disruption to the normal processes of bone maintenance.

Macrophages are highly plastic innate immune cells that contribute to tissue homeostasis, immune surveillance, inflammation resolution, and tissue repair. In bone tissue, macrophages are important components of the bone immune microenvironment and participate in the regulation of bone remodeling through interactions with osteoblasts, osteoclasts, bone marrow mesenchymal stem cell (BMSC), and other stromal or immune cells. Macrophage phenotypes are shaped by local microenvironmental cues and are often simplified into pro-inflammatory M1-like and reparative M2-like states. However, this binary classification does not fully capture macrophage heterogeneity in ageing bone marrow. In particular, macrophages in aged or diseased bone may acquire senescence-associated features that are distinct from ordinary inflammatory activation or classical polarization states.

The accumulating evidence indicates that the imbalance of the bone immune microenvironment is a key pathological process in osteoporosis. Traditionally, studies have focused on the effects of macrophages on the differentiation of osteoblasts or osteoclasts. However, recent discoveries suggest that the status of macrophages is closely related to the interaction of BMSCs within the bone marrow microenvironment and determines different outcomes. Macrophages in young mice can secrete factors that promote the osteogenic differentiation of BMSCs, while this ability is diminished in aged mice. Furthermore, older mice or elderly individuals displayed a marked increase in M1-polarized macrophages, with senescent macrophages exhibiting heightened production of inflammatory mediators.

The precise contribution of macrophage senescence to osteoporosis has only recently begun to be clarified. In this review, we consolidate current evidence on the mechanisms through which macrophage senescence or senescence-associated macrophage dysfunction may contribute to osteoporosis, including autophagy dysregulation, senescence-associated secretory phenotype (SASP)-related factors, lipolytic factors, ageing-related signaling pathways, mitochondrial transfer, and exosome-mediated communication. We also summarize therapeutic strategies related to macrophage senescence or senescence-associated dysfunction in osteoporosis, while emphasizing that many of these mechanisms and interventions are supported by different levels of evidence.

Link: https://doi.org/10.1186/s12979-026-00586-4

Greater Inflammatory Signaling Contributes to Reduced Thermogenesis in Old Age

In mammals, body temperature is maintained in part by mitochondrial uncoupling in fat cells, whereby energy normally used in the generation of the chemical energy store molecule adenosine triphosphate (ATP) is instead diverted to heat tissues. This process of thermogenesis is needed to resist cold temperatures but declines with age for a variety of reasons. Here, researchers identify an important mechanism driving reduced levels of thermogenesis in response to low temperature. The root of the problem is that an inflammatory signal molecule, IL-1β, plays a role in the mechanisms of temperature sensing, but its baseline levels increase with age as a part of the chronic inflammation of aging. This dampens the response to low temperature, preventing initiation of mitochondrial uncoupling for thermogenesis.

Thermogenic adipose tissue undergoes adaptive thermogenesis and is crucial for energy expenditure and thermoregulation. Thermogenic capacity declines substantially with age in rodents and humans, leading to age-related cold sensitivity and metabolic disorders. Brown adipocytes (BAs) and beige adipocytes mediate UCP1-dependent non-shivering thermogenesis. Although substantial progress has been made in identifying the key pathways that activate thermogenesis, most studies have been conducted at the whole-tissue level, leaving the mechanisms governing its activation, maintenance and deactivation incompletely understood.

We previously identified a BA subpopulation with low UCP1 expression (hereafter, BA-L cells) that coexists with the classical, high-UCP1-expressing BAs (hereafter, BA-H cells). Here we show that IL-1β secreted by neutrophils and macrophages stabilizes nearby BAs in the BA-L state. Specifically, IL-1β stabilizes H6PD protein from degradation to ensure the generation of active glucocorticoids, which activate the glucocorticoid receptor (GR, encoded by Nr3c1) and increase the expression of its target gene, regulator of G-protein signalling 2 (Rgs2), thereby suppressing UCP1 expression.

Cold exposure reduces IL-1β levels, depending on sympathetic innervation, leading to H6PD degradation and the conversion of BA-L cells to BA-H cells, thereby enhancing UCP1-dependent thermogenesis. Rising environmental temperatures trigger the opposite events. BA-specific inducible deletion of Nr3c1 during cold exposure locks these cells in the BA-H state, leading to persistent thermogenesis and increased energy expenditure days after the mice return to room temperature. Notably, IL-1β is elevated in aged brown adipose tissue, resulting in a locked low BA-H/BA-L ratio and cold intolerance. Suppressing GR in aged mice restores the BA-H/BA-L ratio, resumes thermogenesis, and increases energy expenditure.

Link: https://doi.org/10.1038/s41586-026-11308-7

Gas6 Contributes to the Spread of Calcification in the Aortic Valve

Calcification is a feature of aging in a number of tissues, and perhaps of greatest concern where it occurs in the vasculature and heart. Some cells in the vasculature respond to the aging environment by maladaptively taking on characteristics of the osteoblast cells responsible for building bone tissue. They deposit calcium structures in vascular tissue, a process which progressively hardens blood vessel walls and, most importantly, structures in the heart. Calcification of heart tissue is ultimately fatal. Unfortunately there are no truly effective therapies to turn back the process of calcification of tissues. About the best on offer is EDTA chelation, which does not have very large effects. Prevention is similarly challenging; there is good evidence for supplementation with vitamin K to slow down calcification, but effect sizes are modest and vary from individual to individual for reasons that remain unclear - much the same situation as exists for LDL cholesterol lowering therapies and atherosclerosis.

Calcification spreads through tissue. In today's open access paper, researchers dig into the exact mechanisms responsible for this spread in aortic valves. They identify Gas6 secreted by senescent cells in the valve as one of the signals driving the adoption of calcifying behavior by neighboring cells. This provides a target for the development of therapies that at least slow down calcification, but perhaps not capable of reversal of existing calcification. Following discovery of a relevant signal molecule, one could in principle also target the molecule biochemistry immediately downstream of the signal, but the researchers suggest that in this case these proteins are poor targets for therapy due to their participation in other, vital functions in heart tissue.

The Senokine Gas6 Promotes Aortic Valve Calcification Through CaMKII-DRP1-Mediated Terminal Scission of Mitochondrial-Derived Vesicles

Calcific aortic valve disease (CAVD) is an age-associated valvular disorder in which calcification expands from discrete foci into adjacent tissue. We investigated whether mitochondrial-derived vesicles (MDVs) released by human valvular interstitial cells (hVICs) exert pro-calcific effects on recipient cells and how MDV release is regulated. Using ex vivo hemodynamic perfusion of human CAVD tissue, multi-omics profiling, live-cell single-organelle tracking, MDV transfer assays, and in vivo Gas6 deletion, we found that calcifying hVICs hypersecreted MDVs that exerted pro-calcific effects in recipient hVICs.

High-resolution imaging showed that mitochondria remodeled into donut-shaped structures under pro-osteogenic conditions; these structures served as physical platforms for MDV budding. Human CAVD valve tissues and hVICs treated with pro-osteogenic medium also exhibited senescence-associated features. Multi-omics profiling identified growth arrest-specific 6 (Gas6), a senokine, among 36 concordantly upregulated candidates. Functional analyzes showed that Gas6 promoted terminal MDV scission while leaving donut-shaped mitochondrial precursor formation intact. Mechanistically, Gas6 promoted intracellular Ca2+ accumulation, calcium/calmodulin-dependent protein kinase II (CaMKII) activation, and dynamin-related protein 1 (DRP1) phosphorylation, supporting a Ca2+-CaMKII-DRP1 axis that facilitates terminal MDV scission.

Pharmacological inhibition of CaMKII or DRP1 reduced MDV hypersecretion and subsequent recipient-cell calcification, and Gas6 deletion in vivo attenuated valvular stenosis, calcification, and fibrotic remodeling. Neither protein, however, represents a straightforward therapeutic target. DRP1 is needed for normal mitochondrial fission, mitophagy, and quality control; systemic inhibition may therefore disrupt essential mitochondrial functions. CaMKII presents similar challenges. It is active in cardiac excitation-contraction coupling, neuronal plasticity, and immune signaling; these broad physiological roles may complicate systemic inhibition. Gas6 may therefore represent a candidate upstream control point. It lies upstream of CaMKII and DRP1 and is secreted, providing a rationale for evaluating Gas6-directed strategies.

Age-Related Synaptic Dysfunction and Possible Approaches to Treatment

Dysfunction of the synaptic connections between neurons in the brain is characteristic of aging and exaggerated in neurodegenerative conditions, particularly Alzheimer's disease. The brain is a collection of neural networks: a neuron extends branching axons that connect to other neurons via synapse structures. When synapses lose function, the network loses function, and cognitive decline is the result. Here, researchers discuss the biochemistry of synapses and a variety of approaches to therapy that might improve matters. They conclude that the most promising approaches at the present time are those focused on reducing the impact of aging on the function of glial cells. Glia in the brain (microglia, astrocytes, and so forth) support the function of neural networks in a broad variety of ways, and their progressive dysfunction is considered an important contribution to age-related issues in axons and synapses.

Disturbances in synaptic transmission, particularly those that imbalance excitatory and inhibitory synapses, contribute to neuronal excitotoxicity in neurodegenerative diseases (NDDs). Such disorders are manifested explicitly in NDD pathology on various components of synaptic transmission, including presynaptic and postsynaptic receptors, along with their modulators. The current repertoire of anti-NDD drugs employed in clinical practice, which specifically target synaptic transmission, may offer a novel therapeutic avenue. However, the intricate mechanisms regulating synaptic transmission in health and disease remain to be elucidated.

In the treatment of NDDs, early screening for risk factors and prophylactic administration of drugs that regulate synaptic transmission homeostasis offer valuable options. Neuronal loss in NDDs may represent a downstream effect of pathogenic factors such as pathological protein aggregation and glial activation. Therefore, therapies that combine upstream pathophysiology, such as anti-amyloid-β antibodies, may provide a more effective solution. Clinical application of amyloid-β antibodies, postsynaptic neurotransmitter modulators, and neuroglia regulators may provide effective early intervention strategies for AD. In particular, glial regulators provide a theoretical basis for drug development through targeted regulation of lipid metabolism and enhancement of the autophagosome-lysosome system.

Finally, neuroinflammation orchestrates synaptic loss while concurrently reducing amyloid levels via the complement cascade. Therapeutic interventions that prevent synaptic transmission impairment and modulate glial-synapse interactions, such as complement inhibitors and TREM2 agonists, hold promise for altering the progression of NDDs. Given the multifactorial complexity of NDD pathophysiology, early glial-synapse targeting may effectively complement current treatments.

Link: https://doi.org/10.1038/s41392-026-02776-4

Senescence in Mesenchymal Stromal Cells as a Driver of Degenerative Aging

Mesenchymal stromal cells are found in stem cell niches, and thus their behavior influences the activity and capabilities of the stem cell populations that support tissues. Here, researchers argue for cellular senescence in mesenchymal stromal cells to be an important mediator of degenerative aging, via its negative effects on the activity of stem cells. Some of the better studied stem cell populations, such as muscle stem cells, are established to remain capable of function into late life, but are steered into quiescence and reduced activity by the aged signal environment they find themselves in. Senescent cells provide a sizable component of the difference in signaling between a young tissue and old tissue.

Aging is accompanied by a progressive decline in tissue regenerative capacity, driven by intrinsic stem cell dysfunction and age-associated deterioration of the surrounding stem cell niche. Mesenchymal stromal cells (MSCs) are ubiquitous components of stem cell niches, where they integrate structural, metabolic, inflammatory, and paracrine cues to regulate stem cell quiescence, activation, and differentiation. With age, MSCs undergo functional decline and senescence, altering their secretory and signaling profiles. Across tissues, MSC senescence emerges as an intermediate amplifier of aging: molecular, metabolic, epigenetic, and inflammatory stressors promote the senescent state, which converts these upstream insults into chemokine imbalance, chronic inflammation, and progressive loss of stem cell support.

Here, we synthesize classical and emerging literature to examine how age-associated changes in MSC chemokine synthesis contribute to stem cell aging, and we propose a synthesis-based model in which MSCs translate age-associated stressors into altered chemokine repertoires that disrupt stem cell-supportive signaling. We also discuss therapeutic strategies, including chemokine-directed therapies, senolytics, and MSC rejuvenation, that may restore regenerative capacity by normalizing MSC-derived signals. Together, the evidence identifies dysregulated chemokine synthesis as a conserved mechanism linking tissue-resident MSC aging to declining regenerative capacity.

Link: https://doi.org/10.1111/acel.70780

A Senolytic Vaccine that Also Improves Dendritic Cell Function

Cells become senescent throughout life, either because they reach the Hayflick limit on replication, or in response to various stresses. The pathological accumulation of senescent cells that contributes to the onset and progression of age-related conditions only starts to occur in later life, however. This takes place because the immune system becomes progressively less capable of prompt clearance of senescent cells. In youth, senescence is transient because these cells are destroyed by immune cells: a senescent cell secretes inflammatory signals that attract the attention of the immune system. In later life, however, senescent cells begin to employ signals and surface markers that allow for immune evasion, while at the same time the immune system becomes less capable of destroying problematic cells.

Senolytic therapies are those that selectively destroy senescent cells. A range of different approaches have been demonstrated in animal and human studies to achieve this goal, as senescent cells are biochemically quite distinct from normal cells. One of the most interesting approaches to the selective destruction of senescent cells is vaccination, as it offers the possibility of a single treatment that produces long-lasting enhanced immune clearance of senescent cells, and even improved clearance in old age despite the many impediments to immune function that exist in later life. A number of research groups and biotech companies have demonstrated forms of senolytic vaccine and other immunotherapies that induce the immune system to destroy senescent cells.

Today's open access paper describes a clever approach to a senolytic vaccine that not only instructs the immune system to attack senescent cells, but also reduces the impact of cellular senescence - and consequential age-related impairment - in the dendritic cell population responsible in part for coordinating immune responses. We might expect to see more vaccines employ this strategy in the future; it isn't only restricted to immunotherapies targeting senescence cells.

A Bi-Adjuvant Senolytic Nanovaccine Modulating Dendritic Cell Senescence Ameliorates Aging-Related Metabolic Dysfunction

The identification of seno-antigens has enabled senolytic vaccines to achieve antigen-directed senescent cell clearance with improved safety profiles, representing an innovative paradigm in geroscience. However, the development of effective senolytic vaccines is fundamentally challenged by weak senescence-antigen immunogenicity, aging-impaired dendritic cell (DC) function, and senescent cell-mediated immunosuppression. Notably, in aged organisms, DC senescence emerges as a critical obstacle to the efficacy of senolytic vaccination. Therefore, an effective immunosenolytic strategy requires precise presentation of seno-antigens coupled with immune rejuvenation to overcome DC priming deficits and achieve optimal senescent cell elimination.

DCs undergo dynamic, age-dependent functional changes throughout life and mirror the immunological age of the host. Senescent DCs exhibit cell-intrinsic hyperactivation of the PI3K/AKT pathway, which disrupts antigen cross-presentation and CD8+ T-cell priming against seno-antigens. These immunological constraints severely undermine the efficacy of current senolytic vaccines, particularly those targeting poorly immunogenic seno-antigens.

Emerging nanotechnological platforms enable the engineering of multifunctional senolytic vaccines that integrate antigen delivery and immune modulation. Nanoarchitectured vaccines can precisely deliver adjuvants to senescent DCs to restore their activation without triggering excessive systemic inflammation, consequently amplifying vaccine-elicited immunity in aged individuals. Such senolytic vaccines necessitate a highly coordinated assembly to simultaneously enhance antigen immunogenicity and actively modulate DC senescence, thereby driving the efficient cytotoxic T-lymphocyte activation required for targeted senolysis. In this integrated gerotherapeutic system, the bi-adjuvant platform operates through two functionally distinct, compartmentalized mechanisms: direct intracellular uptake of the cationic spider silk protein variant CK5 scaffold by local DCs attenuates their senescence-associated signaling to rescue antigen-presenting competence, whereas distant senescent adipocytes undergo extrinsic, targeted elimination orchestrated by vaccine-activated Gpnmb-specific CD8+ cytotoxic T lymphocytes.

Across multiple aging mouse models, immunization orchestrated targeted clearance of Gpnmb+ senescent adipocytes, profoundly ameliorating metabolic dysfunction and extending lifespan. This multifunctional biomaterial platform integrates seno-antigen immunogenicity enhancement with the restoration of aged DC function, providing a promising proof-of-concept for antigen-directed gerotherapeutics.

Lipid Dysfunction in Macrophages Implicated in Lung Fibrosis

Fibrosis is a dysfunction of tissue maintenance in which fibroblast cells build excessive extracellular matrix structures, like small-scale scars throughout a tissue, disruptive of structure and function. A full understanding of how fibrosis develops in the lung remains to be established, which is one of the reasons why curative therapies for idiopathic pulmonary fibrosis have yet to be created. Approaches involving the removal of senescent cells seem promising, but early and possibly useful senolytic drugs are low-cost generics and supplements, and so funds are not available for usefully large clinical trials. Here, researchers propose that lipid metabolism dysfunction leading to an accumulation of cholesterol in macrophages in lung tissue is the primary mechanism in the development of pulmonary fibrosis. They demonstrate that inducing this cholesterol accumulation generates fibrosis.

Macrophages are essential for lung homeostasis and repair after injury, yet they can also promote pathological remodeling. Although mechanisms that sustain fibrosis are increasingly well defined, the endogenous events that initiate fibrotic remodeling remain incompletely understood. We examined mice deficient in the intracellular sterol transporter ABCG1 and assessed the temporal relationship between macrophage lipid accumulation, collagen deposition, and fibrotic remodeling. Lipidomic profiling was performed on Abcg1-deficient macrophages and macrophages isolated during early experimental fibrosis. Candidate lipid species were tested for their ability to activate fibroblasts in vitro, and therapeutic interventions targeting macrophage cholesterol trafficking or fibroblast lipid uptake were evaluated in vivo.

Loss of ABCG1 caused lipid accumulation in alveolar macrophages early before collagen deposition and lung remodeling. Lipidomic analyses revealed conserved enrichment of polyunsaturated acyl tails within complex lipid species in Abcg1-deficient macrophages and macrophages from early-stage experimental fibrosis. These lipids directly activated fibroblasts and induced fibrotic gene expression in vitro. Restoration of macrophage cholesterol trafficking or inhibition of fibroblast lipid uptake prevented fibrotic remodeling in vivo.

Macrophage cholesterol dysregulation is sufficient to initiate spontaneous lung fibrosis. These findings identify a lipid-mediated macrophage-fibroblast axis as an endogenous driver of fibrotic remodeling and suggest that targeting macrophage lipid handling or fibroblast lipid uptake may represent a therapeutic strategy in fibrotic lung disease.

Link: https://doi.org/10.1093/ajrcmb/aanag199

Adult Castration is More Effective than Castration During Development at Extending Life in Mice

Sex hormones and other signals generated by the testicles are considered to accelerate aging in males, as demonstrated by the fact that castration in males and sterilization in females slows aging and extends life span in most higher animals. Here, researchers note that the effect on life span in mice is larger when castration is performed at an adult age, equivalent to mid-30s in a human, rather than during development. This say something about the way in which influences change over a life span; sex hormones are beneficial early in life, but become harmful, on balance, in later life. This is characteristic of what is understood of the evolution of aging, in that early life reproductive success is the determinant of success, and this encourages the evolution of systems that work well at the outset and then fall apart or become harmful in later life. Aging emerges from the strong focus of selection pressure on early life capabilities.

Men live shorter lives than women across nearly all human populations, a disadvantage that extends across most biological causes of death and that cannot be fully explained by behavioral or environmental differences. This suggests that fundamental biological mechanisms contribute to elevated male mortality. Our previous work implicated testicular factors as a major contributor, showing that prepubertal castration extends male lifespan to that of females in UM-HET3 mice, a genetically heterogeneous stock. However, it remains unknown when testicular factors begin to exert their detrimental effects on mortality.

Here, we castrated UM-HET3 males before puberty (20 days), after puberty (60 days), or immediately before the typical rise in male mortality (240 days). Castration at all three ages prevented the early male mortality and increased median lifespan by 19.3%, 25.8%, and 32.9%, respectively. The comparable survival benefits of prepubertal and postpubertal castration indicate that exposure to the pubertal surge in testicular factors, including male sex hormones, is not responsible for establishing the male longevity disadvantage. Remarkably, castration at 240 days not only preserved the survival benefit of earlier castration but produced significantly greater survival than earlier castration, suggesting that testicular exposure before 240 days is actually beneficial.

The immediate prevention of excess male mortality following castration at 240 days also indicates that the responsible testicular factors act rapidly and that their continued presence is necessary to sustain elevated male mortality. Longitudinal body-composition measurements further revealed that castration shifted males toward a female-like phenotype, characterized by reduced lean mass and continued fat accumulation into later life. Our findings reveal opposing age-dependent effects of testicular factors on survival and narrow the potential therapeutic window to later adulthood.

Link: https://doi.org/10.64898/2026.10.19.760267

Vasodilatory and Vibratory Treatment Improves Glymphatic Drainage in Humans

The glymphatic system provides pathways for cerebrospinal fluid to drain from the brain into the body, carrying with it metabolic waste from the brain. This waste material includes the protein aggregates associated with various neurodegenerative conditions, such as amyloid-β. The glymphatic system is primarily active during sleep, and relies upon (a) blood vessel pulsation to drive fluid flow in the perivascular spaces that run parallel to blood vessels, (b) water channels such as AQP-4 in astrocytes to permit fluid to enter perivascular spaces, and (c) the lymphatic vessels of the neck. Further, a portion of the glymphatic system runs through the cribriform plate bone behind the nose, and that relies upon channels in the plate remaining open. All of these points of reliance are negatively impacted by age, degrading fluid flow from the brain, and allowing metabolic waste to build up. This appears to be a meaningful contribution to the onset and development of neurodegenerative conditions.

Researchers have conducted proof of principle studies in animals and people for a range of possible approaches to improving glymphatic drainage of cerebrospinal fluid in aged individuals. Drugs that restore blood and lymphatic vessel smooth muscle function to help with pulsation-driven fluid fluid flow. Delivery of intermittent CO2 during sleep. Various gene therapies and small molecule drugs to improve AQP-4 function in astrocytes. And so forth. In today's open access paper, researchers provide evidence from a small human trial for a combination of vasodilatory therapy (using the very old approach of nitroglycerine to increase vasodilatory nitric oxide signaling) and vibration during sleep to improve glymphatic function. The addition of vibration is an interesting choice, given that there is animal study evidence for vasodilation alone to improve glymphatic drainage.

Vasomechanic treatment is associated with increased efflux of human brain proteins

The efficient removal of soluble metabolites and proteins from interstitial and cerebrospinal fluids (I/CSF) is essential for maintaining brain homeostasis. Impairment of brain clearance pathways has been linked to the earliest stages of neurodegenerative disease, preceding neuronal loss by years or decades. Experimental and clinical studies demonstrate that impaired clearance of soluble amyloid-β (Aβ) and phosphorylated tau protein from the CSF leads to their accumulation within perivascular and interstitial compartments, promoting their aggregation and accelerating neuropathology.

Recent findings suggest that CSF efflux can be modulated through physiological mechanisms that are both therapeutically targetable and monitorable in humans. Acute systemic vasodilation caused by hypotensive drugs such as nicardipine and sodium nitroprusside (SNP) has emerged as a potent enhancer of CSF solute efflux in rodents. Nitric oxide (NO) donors such as SNP increase movement of intracisternal tracers from the cranial cavity to the blood, predominantly via cervical lymph nodes, an effect that is accompanied by improved downstream lymphatic function. Local NO delivery to neck lymphatic plexuses similarly enhances efflux of intracranial tracers, demonstrating that modulation of vascular tone can directly augment CSF transport along g/lymphatic pathways

Mechanical stimulation of Piezo1, a mechanosensitive cation channel expressed ubiquitously in all tissues including vascular and lymphatic endothelia, presents a complementary route for modulating neurofluid flow. Recent work shows that even light mechanical stimulation activates Piezo1, increases endothelial NO synthase (eNOS) activity, and restores age-related deficits in cervical lymphatic efflux. Piezo1 activation also increases meningeal lymphatic drainage and improves learning and memory in mice.

In this study (EudraCT 2021-000625-27), we investigated the effects of sublingual NO and Piezo1-targeted whole-body vibrations (WBVp) in healthy adults (n = 29) using multimodal neuroimaging and blood biomarker analysis. The combined intervention (NO+WBVp) was associated with correlating changes in brain fluid dynamics and increased blood levels of soluble brain-derived proteins (Aβ40 and Aβ42, GFAP). These effects increased with age and the magnitude of NO-induced hypotension. The interventions were well tolerated under controlled experimental conditions. Overall, the findings are consistent with transient redistribution of brain-derived proteins toward circulation, suggesting a potential non-invasive approach to increase neurofluidic solute efflux in humans.

Overexpression of Myc and Cyclin T1 via mRNA Therapy Improves Regeneration of Heart Tissue

The heart regenerates poorly in comparison to most other tissues in the body, scarring rather than recovering function, and this is one of the reasons why heart attacks have such poor outcomes for patients even given survival of the initial event. Researchers here demonstrate that overexpression of both Myc and cyclin T1 can be used to provoke greater regeneration following injury to heart tissue. The researchers used messenger RNA (mRNA) in order to produce transient overexpression, but development of a human therapy would likely require a better delivery system than was used in this proof of concept study.

Across regenerative tissues and species, Myc serves as a pivotal, nonredundant instructor of tissue regeneration following injury. Myc expression in differentiated tissues is stringently controlled and typically maintained at a low level. Following damage in a tissue capable of regeneration, local mitogenic stimulation leads to a transient increase in short-lived Myc protein followed by a rapid burst of proliferation. The regenerative Myc response has been observed across regenerative species and repair is attenuated if Myc activity is blocked.

The mammalian heart is characterized by low regenerative capacity. The lack of regeneration in the myocardium is a result of the low proliferative ability of adult cardiomyocytes. We have determined that ectopic expression of Myc alone cannot drive efficient cell division of cardiomyocytes, due to the low levels of P-TEFb in adult cardiomyocytes. P-TEFb is a protein complex comprising CDK9 and cyclin T1 that, following stimulation, is recruited to and phosphorylates RNA polymerase II to enable productive transcription. Cyclin T1 is the key factor controlling the P-TEFb levels in cardiomyocytes.

Combined overexpression of Myc and cyclin T1 in cardiomyocytes leads to efficient Myc-driven transcription that can drive juvenile and adult mouse cardiomyocyte proliferation in vivo, leading us to speculate whether this genetic combination could be explored for therapeutic benefits after cardiac injury. Here, using transgenic models and a mRNA therapeutic, we show that Myc and cyclin T1 require transient induction for cardiomyocyte proliferation that leads to myocardial repair and functional recovery after myocardial infarction in mice. This research provides a strategy to translate Myc-cyclin T1 coexpression for cardiac regeneration to address serious unmet needs in the treatment of cardiovascular disease.

Link: https://doi.org/10.1038/s44161-026-00910-7

Assessing Impaired Macroautophagy in Aged Skin Cells

Autophagy is a category of several different cell maintenance processes that converge on delivering broken or unwanted proteins and structures to a lysosome for disassembly and recycling. Confusingly, autophagy is also used as the common name for one of these processes, macroautophagy: a target is engulfed in an autophagosome, which then is transported to a lysosome and merges with it to deposit the cargo for recycling. One of the challenges inherent in measuring autophagy is that one has to look at all of the stages of the process in order to understand how the system functions; looking at just one stage can be misleading, as it could appear completely normal or even hyperactive if a later stage is failing, for example. Here, researchers characterize the state of macroautophagy in fibroblast cells from aged skin, identifying the components that are failing, and thus degrading cell function.

Autophagy is a cytoprotective (cellular degradation and recycling) pathway that maintains homeostasis during starvation or stress, and whose activity is associated with extended lifespan. This multi-step process comprises autophagosome formation and maturation, autophagosome-lysosome fusion, and cargo degradation. Analysis of autophagy flux is necessary to precisely design therapeutic interventions aimed at restoring autophagy in aging.

The autophagy flux was comprehensively analyzed in human skin fibroblasts from donors of different ages (20-96 years old), a cell system that retains age-associated cellular and molecular signatures. The subcellular localization and activity of the master transcription factor of autophagy and lysosome biogenesis, TFEB, was analyzed by confocal microscopy assays and transcriptional expression of TFEB target genes (RT-qPCR) respectively. The autophagy flux was evaluated by monitoring the autophagy markers LC3 and p62 by Western blotting and confocal microscopy analyses, using inhibitor drugs to block autophagy or lysosomal activity. Autophagosome maturation and autophagosome-lysosome fusion were analyzed by colocalizing LC3 with Sintaxin-17 and LC3 with the lysosomal protein LAMP1 respectively, using inhibitor drugs and confocal microscopy assays. The analysis of lysosomal morphology and function was evaluated by lysobrite dye staining and live-cell confocal microscopy analysis.

The initial stages of autophagy, including activation of TFEB, and autophagosome formation, remained apparently functional in fibroblast aging. In contrast, the rate of both autophagosome maturation and autophagosome-lysosome fusion, as well as the lysosomal function appears to be altered in aged fibroblasts. Specifically, enlarged dysfunctional lysosomes were identified as a hallmark of the fibroblasts of the 96-year-old donor. This lysosomal dysfunction may lead to a reduced ability to degrade canonical autophagy markers, LC3-II and p62, and the accumulation of lipofuscin. Overall, the results provide evidence that autophagy flux is impaired at the late stages in aged fibroblasts, specifically in autophagosome maturation and autophagosome-lysosome fusion steps.

Link: https://doi.org/10.3389/fragi.2026.1971981